Videos

ALPHA3 highlights off-the-shelf allogeneic CAR T in community clinics, reducing leukapheresis hurdles and speeding up delivery.

Phase 2 ALPHA3 shows cema-cel in MRD-positive large B-cell lymphoma has no CRS/ICANS so far, enabling outpatient consolidation with manageable adverse effects.

Interim ALPHA3 data show cema-cel clears ctDNA MRD in high-risk DLBCL after frontline therapy, prompting continued study of consolidation CAR T.

Why frontline CLL care shifts to zanubrutinib: simple daily BTK inhibitor therapy cuts infusions, eases pill burden, adds flexibility.

Six-year data show zanubrutinib remains well tolerated, with rare atrial fibrillation, low bleeding, and no new safety concerns.

Six-year Sequoia data show zanubrutinib in frontline CLL extends PFS far beyond bendamustine‑rituximab, delaying next treatment.

Six-year Sequoia data show zanubrutinib in frontline CLL extends PFS far beyond bendamustine‑rituximab, delaying next treatment.

For high-risk CLL, experts favor continuous BTK inhibitors and weigh venetoclax visit demands to match frontline therapy to lifestyle.

Experts explain racial gaps in molecular testing and how limited trial diversity affects treating HER2-mutant lung cancer in Black patients.

Compare oral vs IV HER2-targeted lung cancer therapies, including zangertinib and antibody–drug conjugates, with response rates and access considerations.

Explore how taletrectinib's CNS penetration may delay brain metastases and reduce the need for radiation in non–small cell lung cancer patients with ROS1.

Compare infusion schedules and travel burden as new subcutaneous therapy shifts to quick monthly doses versus chemo every three weeks.

In this final episode, Dr. Doroshow examines how HER2-mutant non-small cell lung cancer treatment will evolve over the next two years, then synthesizes key takeaways from Sandra's case.

This episode addresses how second-line HER2-directed therapy selection influences subsequent treatment options in advanced HER2-mutant non-small cell lung cancer.

Weigh amivantamab–lazertinib skin rash options against chemo neutropenic fever and fatigue, with practical supportive-care tips.

Early study data show community oncology matches or beats hospital cancer outcomes at lower cost, boosting local access, better experience, and payment reform calls.

Heather Stefanski, MD, PhD, discusses the significance of reducing the dose of post-transplant cyclophosphamide in the OPTIMIZE trial.

Zongertinib shows strong tolerance and 70%+ responses in HER2-mutant metastatic NSCLC, with a pivotal Phase III trial versus standard chemo-immunotherapy underway.

Weight-based zanjohber niv dosing guide: adjust for CYP3A inhibitors and use early liver tests to avoid dose reductions.

Broad NGS guides metastatic NSCLC care, spotlights common HER2/ERBB2 variants, and explains when liquid biopsy falls short for targeted therapy.

Lilit Karapetyan, MD, MS, discusses the importance of considering TIL therapy for melanoma in advance and not as a last resort.

Ohio State’s BRIDGE program coordinates age-tailored cancer care, tackling fertility, careers, and research gaps to transform outcomes for AYA patients.

CAR T therapy spreads beyond academic centers, but insurance, cost and policy gaps keep most eligible lymphoma patients from receiving it.

Learn how zangontinib affects statins and liver risk, when to switch to pravastatin, and how to monitor labs remotely for hepatitis B safety.

Learn how zangontinib affects atorvastatin, raises liver-risk, and why frequent LFTs plus entecavir may prevent hepatitis B reactivation.

A new program for young cancer patients breaks disease silos, showing how multidisciplinary teamwork improves coordination, insights, and care.

Rawan Faramand, MD, discusses how reducing the cost of GVHD therapy could benefit health systems.

EGFR lung cancer trials show combo therapy better prevents brain metastases, improving intracranial response and PFS compared with osimertinib alone.

Dr. Doroshow addresses financial toxicity as a central concern in Sandra's case and broader challenge in HER2-directed therapy access. Sandra has high-deductible Affordable Care Act marketplace plan with $6,000 annual deductible, is currently on medical leave with uncertain prospects for returning to work and is understandably worried about out-of-pocket expenses that reset each calendar year.

New trial data weigh EGFR lung cancer first-line combos, hinting amivantamab–lazertinib may edge osimertinib plus chemo, especially with TP53.